The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-11 and is reviewed periodically as new material appears.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Noriega was educated first at the Escuela República de México, and later at the Instituto Nacional, a well-regarded high school in Panama City that had produced a number of nationalist political leaders. He was described as an "oddly serious child," a bookish student always neatly dressed by his godmother. During his time in the Instituto Nacional he met his older half-brother Luis Carlos Noriega Hurtado, a socialist activist and also a student at the school: Manuel had not previously met his siblings. Manuel began living with Luis, who introduced him to politics, including recruiting him into the Socialist Party's youth wing. Luis Noriega would later direct Panama's electoral tribunal. During his time in the socialist youth group, Noriega took part in protests and authored articles criticizing the U.S. presence in Panama. He is reported to have begun his association with the U.S. intelligence services at this time, providing information about the activities of his comrades. A$10.70 payment in 1955 was the first he received from the U.S. Noriega intended to become a doctor, but was unable to secure a place in the University of Panama's medical school. After graduating from the Instituto Nacional, Noriega won a scholarship to Chorrillos Military School in the Peruvian capital of Lima, with the help of Luis, who had by then received a position in the Panamanian embassy in Peru. Noriega began studying in Lima in 1958. While there, he made the acquaintance of Roberto Díaz Herrera, then studying at the Peruvian Police academy, who later became a close ally.
== External links == "P2Y Receptors: P2Y2". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2016-03-03. Retrieved 2008-12-09. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
=== Radionuclides with half-lives of 104 years to 108 years === Ordered by half-life. Some of these are known to have been present in the early Solar System (marked "ESS", meaning the first few million years of the Solar System's history) from an excess of their decay products.
Growth hormone-releasing peptide 6 (GHRP-6) (developmental code name SKF-110679), also known as growth hormone-releasing hexapeptide, is one of several synthetic met-enkephalin analogues that include unnatural D-amino acids, were developed for their growth hormone-releasing activity and are called growth hormone secretagogues. They lack opioid activity but are potent stimulators of growth hormone (GH) release. These secretagogues are distinct from growth hormone releasing hormone (GHRH) in that they share no sequence relation and derive their function through activation of a completely different receptor. This receptor was originally called the growth hormone secretagogue receptor (GHSR), but due to subsequent discoveries, the hormone ghrelin is now considered the receptor's natural endogenous ligand, and it has been renamed as the ghrelin receptor. Therefore, these GHSR agonists act as synthetic ghrelin mimetics. It has been discovered that when GHRP-6 and insulin are administered simultaneously, GH response to GHRP-6 is increased (1). However, the consumption of carbohydrates and/or dietary fats, around the administration window of GH secretagogues significantly blunts the GH release. A recent study in normal mice showed significant differences in body composition, muscle growth, glucose metabolism, memory and cardiac function in the mice being administered the GHRP-6 (2). There are still many questions regarding this fairly new compound.
This category includes the Community of Latin American and Caribbean States (CLACS), Council of Europe (CoE), European Union (EU), Eurasian Economic Union (EAEU), Energy Community, North Atlantic Treaty Organization (NATO), Economic Community of West African States (ECOWAS), Organization for Security and Co-operation in Europe (OSCE), African Union (AU), Organization of American States (OAS), Association of Caribbean States (ACS), Association of Southeast Asian Nations (ASEAN), Islamic Development Bank, Union of South American Nations, Asia Cooperation Dialogue (ACD), Pacific Islands Forum, South Asian Association for Regional Cooperation (SAARC), Asian-African Legal Consultative Organization (AALCO) and the Organisation of Eastern Caribbean States (OECS).
Sources: en.wikipedia.org
=== Transport to the brain === Vitamin C does not pass from the bloodstream into the brain, although the brain is one of the organs that have the greatest concentration of vitamin C. Instead, DHA is transported through the blood–brain barrier via GLUT1 transporters, and then reduced back to ascorbic acid.
In traditional amphetamine pharmacology, TAAR1 activation triggers intracellular phosphorylation signaling cascades that facilitate and optimize the structural reversal of monoamine transporters (MATs) to allow efficient neurotransmitter efflux. Because cathinones fail to activate TAAR1, this phosphorylation is absent, rendering carrier-mediated efflux less efficient. Consequently, displaced neurotransmitters tend to accumulate and linger within the cytoplasm rather than being cleanly exported to the synaptic cleft, promoting intracellular auto-oxidation, and faster depletion. Psychostimulants differ in their relative affinity for DAT, SERT and NET. In a study done on brain cells of male rats 3-CMC was found to interact on a relatively similar level with DAT and NET as mephedrone, while it interacts significantly less with SERT. Another study done on male rats also concludes that 3-CMC causes more release of dopamine in proportion to serotonin whereas mephedrone releases relatively more serotonin. 3-CMC produces hyperlocomotion, a psychostimulant-like effect, in rodents. It substitutes for cocaine in drug discrimination tests in monkeys. The drug is less potent in substituting for cocaine than methcathinone, which has been theorized to be due to its greater capacity to induce serotonin release and to thereby inhibit its own reinforcing effects.
where ABCD+ is selected by MS1 and dissociates by two pathways, forming either AB+ or CD+. The ions are selected sequentially by MS2 and detected. Parallel reaction monitoring (PRM) is the application of SRM with parallel detection of all transitions in a single analysis using a high resolution mass spectrometer.
=== 1990–1992: Facelift and Sap === Alice in Chains soon became a top priority of the label, which released the band's first official recording in July 1990, a promotional EP called We Die Young. The EP's lead single, "We Die Young", became a hit on metal radio. After its success, the label rushed Alice in Chains' debut album into production with producer Dave Jerden. Cantrell stated the album was intended to have a "moody aura" that was a "direct result of the brooding atmosphere and feel of Seattle." The resulting album, Facelift, was released on August 21, 1990, peaking at number 42 in mid-1991 on the Billboard 200 chart. Facelift was not an instant success, selling under 40,000 copies in the first six months of release, until MTV added "Man in the Box" to regular daytime rotation. The single hit number 18 on the Mainstream rock charts, with the album's follow up single, "Sea of Sorrow", reaching number 27, and in six weeks Facelift sold 400,000 copies in the US. The album was a critical success, with Steve Huey of AllMusic citing Facelift as "one of the most important records in establishing an audience for grunge and alternative rock among hard rock and heavy metal listeners." Sammy Hagar claimed he invited the band to tour with Van Halen after he saw the music video for "Man In The Box" on MTV.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.